S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
S&P 500   3,004.52 (+0.28%)
DOW   26,833.95 (+0.17%)
QQQ   192.22 (+0.19%)
AAPL   243.18 (+1.34%)
FB   186.19 (+2.11%)
MSFT   137.24 (+0.64%)
GOOGL   1,257.63 (+1.32%)
AMZN   1,762.17 (-0.20%)
CGC   21.75 (+2.84%)
NVDA   195.09 (-0.27%)
MU   44.66 (+0.00%)
BABA   169.92 (+0.02%)
GE   9.14 (+0.88%)
TSLA   254.68 (-0.35%)
AMD   31.36 (-0.48%)
T   37.74 (-1.13%)
F   9.21 (+1.54%)
ACB   3.67 (+2.51%)
PRI   125.75 (-0.04%)
NFLX   271.27 (+1.72%)
BAC   31.42 (+0.71%)
GILD   66.58 (+1.09%)
DIS   131.13 (-0.96%)
Log in

Opiant Pharmaceuticals Stock Price, News & Analysis (NASDAQ:OPNT)

$15.60
+0.47 (+3.11 %)
(As of 10/23/2019 04:00 PM ET)
Today's Range
$14.69
Now: $15.60
$15.67
50-Day Range
$13.51
MA: $14.69
$16.48
52-Week Range
$9.98
Now: $15.60
$19.14
Volume16,800 shs
Average Volume20,441 shs
Market Capitalization$63.04 million
P/E RatioN/A
Dividend YieldN/A
Beta0.32
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Read More…

Industry, Sector and Symbol

Industry Metal mining
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPNT
CUSIPN/A
Phone310-598-5410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.98 million
Book Value$4.38 per share

Profitability

Net Income$-21,190,000.00

Miscellaneous

Employees16
Market Cap$63.04 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.


Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) announced its quarterly earnings results on Thursday, August, 8th. The technology company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.86. The technology company earned $6.78 million during the quarter, compared to analysts' expectations of $3.91 million. Opiant Pharmaceuticals had a negative net margin of 11.78% and a negative return on equity of 12.74%. View Opiant Pharmaceuticals' Earnings History.

When is Opiant Pharmaceuticals' next earnings date?

Opiant Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Opiant Pharmaceuticals.

What price target have analysts set for OPNT?

1 Wall Street analysts have issued 1 year target prices for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 169.2% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.

What is the consensus analysts' recommendation for Opiant Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.

Has Opiant Pharmaceuticals been receiving favorable news coverage?

News coverage about OPNT stock has been trending somewhat negative this week, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Opiant Pharmaceuticals earned a news impact score of -1.5 on InfoTrie's scale. They also assigned news coverage about the technology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Opiant Pharmaceuticals.

Are investors shorting Opiant Pharmaceuticals?

Opiant Pharmaceuticals saw a drop in short interest in September. As of September 30th, there was short interest totalling 30,800 shares, a drop of 11.2% from the August 30th total of 34,700 shares. Based on an average daily trading volume, of 19,900 shares, the short-interest ratio is currently 1.5 days. Approximately 0.9% of the shares of the stock are short sold. View Opiant Pharmaceuticals' Current Options Chain.

Who are some of Opiant Pharmaceuticals' key competitors?

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Vodafone Group (VOD), Vodafone Group (VOD), Canopy Growth (CGC), Synchrony Financial (SYF), Cronos Group (CRON), Cyberark Software (CYBR), Sangamo Therapeutics (SGMO) and Xilinx (XLNX).

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the folowing people:
  • Dr. Roger Crystal, CEO & Director (Age 43)
  • Mr. David D. O'Toole, Chief Financial Officer (Age 60)
  • Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
  • Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
  • Mr. Quan Vu, VP of Corp. Devel.

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $15.60.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $63.04 million and generates $13.98 million in revenue each year. The technology company earns $-21,190,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.View Additional Information About Opiant Pharmaceuticals.

What is Opiant Pharmaceuticals' official website?

The official website for Opiant Pharmaceuticals is http://www.opiant.com/.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]


MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  476
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: What is the Coverage Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel